Invented by Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane, Ecole Polytechnique Federale de Lausanne EPFL
One of the key advantages of erythrocyte-binding therapeutics is their ability to target specific cells in the body. Unlike traditional medications, which can affect all cells in the body, erythrocyte-binding therapeutics are designed to bind only to red blood cells. This targeted approach can reduce the risk of side effects and improve the efficacy of the treatment.
Another advantage of erythrocyte-binding therapeutics is their versatility. These drugs can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. For example, erythrocyte-binding therapeutics can be used to deliver chemotherapy drugs directly to cancer cells, reducing the risk of damage to healthy cells.
The market for erythrocyte-binding therapeutics is expected to grow rapidly in the coming years. According to a report by Grand View Research, the global erythrocyte-binding therapeutics market is expected to reach $2.8 billion by 2025, growing at a compound annual growth rate of 7.5%. This growth is being driven by increasing investment in research and development by pharmaceutical companies, as well as the growing demand for targeted therapies.
One of the key challenges facing the erythrocyte-binding therapeutics market is the high cost of development and production. Developing these drugs requires significant investment in research and development, as well as specialized manufacturing processes. However, the potential benefits of these drugs, including improved efficacy and reduced side effects, make them an attractive investment for pharmaceutical companies.
In conclusion, the market for erythrocyte-binding therapeutics is rapidly growing, driven by increasing investment in research and development and the growing demand for targeted therapies. These drugs have the potential to treat a wide range of diseases, and their targeted approach can reduce the risk of side effects and improve the efficacy of the treatment. While there are challenges facing the market, the potential benefits of erythrocyte-binding therapeutics make them an attractive investment for pharmaceutical companies.
The Ecole Polytechnique Federale de Lausanne EPFL invention works as follows
Peptides that bind specifically to erythrocytes have been described. These peptidic ligands have specific sequences or antibodies that bind to erythrocytes. These peptides can be made as molecular-fusions with therapeutic agents or targeting peptides. The fusions may result in immunotolerance.
Background for Erythrocyte-binding therapeutics
INCORPORATION BY RESFERENCE TO MATERIAL IN ASCII TXT FILE”.
Bi-Specific protein Constructs to bind Antigens to Erythrocytes”.
Therapeutic Depletion Of Antigen-Specific Immunes Using Erythrocyte Binding Antigens
Aptamers For Specific Binding Of Erythrocytes”.
Erythrocyte binding Ligands for Improved pharmacokinetics
Single Chain Antibodies
Binding Erythrocytes To Particular Sites Such As Tumor Vasculature
Antigen Specific Immunological Tolerance
Example 1 : Characterizing the molecular target of binding to mouse erythrocytes
Example 2 : Characterizing Binding to Erythrocytes in Humans
Example 3 : Inducing antigen-specific immunological tolerance through non-covalent erythrocyte-binding with ERY1 peptide-conjugated antigen or Human Erythrocyte binding Peptide ConjugatedAntigen
Peptide Design & Synthesis
ERY 1-Antigen Conjugation
Microscopy Binding Erythrocytes to Erythrocytes”.
In Vivo Binding & Biodistribution”.
Adopting T Cells
Click here to view the patent on Google Patents.